{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:24:50Z","timestamp":1791059090163,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T00:00:00Z","timestamp":1360800000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Proximal spinal muscular atrophy (SMA), a neurodegenerative disorder that causes infant mortality, has no effective treatment. Sodium vanadate has shown potential for the treatment of SMA; however, vanadate-induced toxicity <jats:italic>in vivo<\/jats:italic> remains an obstacle for its clinical application. We evaluated the therapeutic potential of sodium vanadate combined with a vanadium detoxification agent, <jats:sc>L<\/jats:sc>-ascorbic acid, in a SMA mouse model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Sodium vanadate (200 \u03bcM), <jats:sc>L<\/jats:sc>-ascorbic acid (400 \u03bcM), or sodium vanadate combined with <jats:sc>L<\/jats:sc>-ascorbic acid (combined treatment) were applied to motor neuron-like NSC34 cells and fibroblasts derived from a healthy donor and a type II SMA patient to evaluate the cellular viability and the efficacy of each treatment <jats:italic>in vitro<\/jats:italic>. For the <jats:italic>in vivo<\/jats:italic> studies, sodium vanadate (20 mg\/kg once daily) and <jats:sc>L<\/jats:sc>-ascorbic acid (40 mg\/kg once daily) alone or in combination were orally administered daily on postnatal days 1 to 30. Motor performance, pathological studies, and the effects of each treatment (vehicle, <jats:sc>L<\/jats:sc>-ascorbic acid, sodium vanadate, and combined treatment) were assessed and compared on postnatal days (PNDs) 30 and 90. The Kaplan-Meier method was used to evaluate the survival rate, with <jats:italic>P<\/jats:italic> &lt; 0.05 indicating significance. For other studies, one-way analysis of variance (ANOVA) and Student's t test for paired variables were used to measure significant differences (<jats:italic>P<\/jats:italic> &lt; 0.05) between values.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Combined treatment protected cells against vanadate-induced cell death with decreasing B cell lymphoma 2-associated X protein (Bax) levels. A month of combined treatment in mice with late-onset SMA beginning on postnatal day 1 delayed disease progression, improved motor performance in adulthood, enhanced survival motor neuron (SMN) levels and motor neuron numbers, reduced muscle atrophy, and decreased Bax levels in the spinal cord. Most importantly, combined treatment preserved hepatic and renal function and substantially decreased vanadium accumulation in these organs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Combined treatment beginning at birth and continuing for 1 month conferred protection against neuromuscular damage in mice with milder types of SMA. Further, these mice exhibited enhanced motor performance in adulthood. Therefore, combined treatment could present a feasible treatment option for patients with late-onset SMA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1741-7015-11-38","type":"journal-article","created":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T09:14:06Z","timestamp":1360833246000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Sodium vanadate combined with l-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy"],"prefix":"10.1186","volume":"11","author":[{"given":"Huei-Chun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hung","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Lan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Kai","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Mei","family":"Hsieh-Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Lin-Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,14]]},"reference":[{"key":"795_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.nurx.2006.01.010","volume":"3","author":"CJ Sumner","year":"2006","unstructured":"Sumner CJ: Therapeutics development for spinal muscular atrophy. NeuroRx. 2006, 3: 235-245. 10.1016\/j.nurx.2006.01.010.","journal-title":"NeuroRx"},{"key":"795_CR2","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH: Spinal muscular atrophy. Lancet. 2008, 371: 2120-2133. 10.1016\/S0140-6736(08)60921-6.","journal-title":"Lancet"},{"key":"795_CR3","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/bies.20283","volume":"27","author":"M Briese","year":"2005","unstructured":"Briese M, Esmaeili B, Sattelle DB: Is spinal muscular atrophy the result of defects in motor neuron processes?. BioEssays. 2005, 27: 946-957. 10.1002\/bies.20283.","journal-title":"BioEssays"},{"key":"795_CR4","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1212\/01.wnl.0000183282.10946.c7","volume":"65","author":"D Hirtz","year":"2005","unstructured":"Hirtz D, Iannaccone S, Heemskerk J, Gwinn-Hardy K, Moxley R, Rowland LP: Challenges and opportunities in clinical trials for spinal muscular atrophy. Neurology. 2005, 65: 1352-1357. 10.1212\/01.wnl.0000183282.10946.c7.","journal-title":"Neurology"},{"key":"795_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, Pasiler D, Fr\u00e9zal J, Cohen D, Weissenbach J, Munnich A, Melki J: Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995, 80: 155-165. 10.1016\/0092-8674(95)90460-3.","journal-title":"Cell"},{"key":"795_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/hmg\/4.4.631","volume":"4","author":"NR Rodrigues","year":"1995","unstructured":"Rodrigues NR, Owen N, Talbot K, Ignatius J, Dubowitz V, Davies KE: Deletions in the survival motor neuron gene on 5q13 in autosomal recessive spinal muscular atrophy. Hum Mol Genet. 1995, 4: 631-634. 10.1093\/hmg\/4.4.631.","journal-title":"Hum Mol Genet"},{"key":"795_CR7","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1086\/302160","volume":"63","author":"DW Parsons","year":"1998","unstructured":"Parsons DW, McAndrew PE, Iannaccone ST, Mendell JR, Burghes AH, Prior TW: Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. Am J Hum Genet. 1998, 63: 1712-1723. 10.1086\/302160.","journal-title":"Am J Hum Genet"},{"key":"795_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00439-002-0828-x","volume":"111","author":"S Ogino","year":"2002","unstructured":"Ogino S, Wilson RB: Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet. 2002, 111: 477-500. 10.1007\/s00439-002-0828-x.","journal-title":"Hum Genet"},{"key":"795_CR9","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B: A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA. 1999, 96: 6307-6311. 10.1073\/pnas.96.11.6307.","journal-title":"Proc Natl Acad Sci USA"},{"key":"795_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/hmg\/9.2.259","volume":"9","author":"CL Lorson","year":"2000","unstructured":"Lorson CL, Androphy EJ: An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet. 2000, 9: 259-265. 10.1093\/hmg\/9.2.259.","journal-title":"Hum Mol Genet"},{"key":"795_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1086\/513886","volume":"61","author":"L Campbell","year":"1997","unstructured":"Campbell L, Potter A, Ignatius J, Dubowitz V, Davies K: Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype. Am J Hum Genet. 1997, 61: 40-50. 10.1086\/513886.","journal-title":"Am J Hum Genet"},{"key":"795_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/hmg\/9.3.333","volume":"9","author":"UR Monani","year":"2000","unstructured":"Monani UR, Sendtner M, Coovert DD, Parsons DW, Andreassi C, Le TT, Jablonka S, Schrank B, Rossoll W, Prior TW, Morris GE, Burghes AH: The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-\/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet. 2000, 9: 333-339. 10.1093\/hmg\/9.3.333.","journal-title":"Hum Mol Genet"},{"key":"795_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/3030","volume":"20","author":"DK Gavrilov","year":"1998","unstructured":"Gavrilov DK, Shi X, Das K, Gilliam TC, Wang CH: Differential SMN2 expression associated with SMA severity. Nat Genet. 1998, 20: 230-231. 10.1038\/3030.","journal-title":"Nat Genet"},{"key":"795_CR14","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","volume":"6","author":"DD Coovert","year":"1997","unstructured":"Coovert DD, Le TT, McAndrew PE, Strasswimmer J, Crawford TO, Mendell JR, Coulson SE, Androphy EJ, Prior TW, Burghes AH: The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997, 6: 1205-1214. 10.1093\/hmg\/6.8.1205.","journal-title":"Hum Mol Genet"},{"key":"795_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ng0797-265","volume":"16","author":"S Lefebvre","year":"1997","unstructured":"Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, Dreyfuss G, Melki J: Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997, 16: 265-269. 10.1038\/ng0797-265.","journal-title":"Nat Genet"},{"key":"795_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/71709","volume":"24","author":"HM Hsieh-Li","year":"2000","unstructured":"Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, Li H: A mouse model for spinal muscular atrophy. Nat Genet. 2000, 24: 66-70. 10.1038\/71709.","journal-title":"Nat Genet"},{"key":"795_CR17","doi-asserted-by":"publisher","first-page":"9808","DOI":"10.1073\/pnas.171105098","volume":"98","author":"JG Chang","year":"2001","unstructured":"Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H: Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA. 2001, 98: 9808-9813. 10.1073\/pnas.171105098.","journal-title":"Proc Natl Acad Sci USA"},{"key":"795_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00109-008-0388-1","volume":"86","author":"LK Tsai","year":"2008","unstructured":"Tsai LK, Tsai MS, Ting CH, Li H: Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med (Berl). 2008, 86: 1243-1254. 10.1007\/s00109-008-0388-1.","journal-title":"J Mol Med (Berl)"},{"key":"795_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1172\/JCI29562","volume":"117","author":"AM Avila","year":"2007","unstructured":"Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA, Hartenstein P, Cizman Z, Di Prospero NA, Pellizzoni L, Fischbeck KH, Sumner CJ: Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest. 2007, 117: 659-671. 10.1172\/JCI29562.","journal-title":"J Clin Invest"},{"key":"795_CR20","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/hmg\/ddq023","volume":"19","author":"M Riessland","year":"2010","unstructured":"Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, Garbes L, Fritzsche I, Mende Y, Blumcke I, Hahnen E, Wirth B: SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet. 2010, 19: 1492-1506. 10.1093\/hmg\/ddq023.","journal-title":"Hum Mol Genet"},{"key":"795_CR21","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1093\/hmg\/ddp313","volume":"18","author":"L Garbes","year":"2009","unstructured":"Garbes L, Riessland M, Holker I, Heller R, Hauke J, Trankle C, Coras R, Blumcke I, Hahnen E, Wirth B: LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum Mol Genet. 2009, 18: 3645-3658. 10.1093\/hmg\/ddp313.","journal-title":"Hum Mol Genet"},{"key":"795_CR22","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1172\/JCI46276","volume":"121","author":"F Farooq","year":"2011","unstructured":"Farooq F, Molina FA, Hadwen J, Mackenzie D, Witherspoon L, Osmond M, Holcik M, Mackenzie A: Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. J Clin Invest. 2011, 121: 3042-3050. 10.1172\/JCI46276.","journal-title":"J Clin Invest"},{"key":"795_CR23","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/sj.gt.3301550","volume":"8","author":"ML Zhang","year":"2001","unstructured":"Zhang ML, Lorson CL, Androphy EJ, Zhou J: An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther. 2001, 8: 1532-1538. 10.1038\/sj.gt.3301550.","journal-title":"Gene Ther"},{"key":"795_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/jmg.2007.051177","volume":"45","author":"C Angelozzi","year":"2008","unstructured":"Angelozzi C, Borgo F, Tiziano FD, Martella A, Neri G, Brahe C: Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Med Genet. 2008, 45: 29-31.","journal-title":"J Med Genet"},{"key":"795_CR25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","volume":"82","author":"Y Hua","year":"2008","unstructured":"Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR: Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet. 2008, 82: 834-848. 10.1016\/j.ajhg.2008.01.014.","journal-title":"Am J Hum Genet"},{"key":"795_CR26","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, Krainer AR: Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010, 24: 1634-1644. 10.1101\/gad.1941310.","journal-title":"Genes Dev"},{"key":"795_CR27","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek LM, Hua Y, Rigo F, Matson J, Hung G, Kaye EM, Shihabuddin LS, Krainer AR, Bennett CF, Cheng SH: Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. 2011, 3: 72ra18-10.1126\/scitranslmed.3001777.","journal-title":"Sci Transl Med"},{"key":"795_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, Krainer AR: Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature. 2011, 478: 123-126. 10.1038\/nature10485.","journal-title":"Nature"},{"key":"795_CR29","doi-asserted-by":"publisher","first-page":"e5268","DOI":"10.1371\/journal.pone.0005268","volume":"4","author":"KJ Swoboda","year":"2009","unstructured":"Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson SL, Wood J, Acsadi G, Crawford TO, Kissel JT, Krosschell KJ, D'Anjou G, Bromberg MB, Schroth MK, Chan GM, Elsheikh B, Simard LR: Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One. 2009, 4: e5268-10.1371\/journal.pone.0005268.","journal-title":"PLoS One"},{"key":"795_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.nurt.2008.08.007","volume":"5","author":"M Oskoui","year":"2008","unstructured":"Oskoui M, Kaufmann P: Spinal muscular atrophy. Neurotherapeutics. 2008, 5: 499-506. 10.1016\/j.nurt.2008.08.007.","journal-title":"Neurotherapeutics"},{"key":"795_CR31","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/hmg\/ddl482","volume":"16","author":"CH Ting","year":"2007","unstructured":"Ting CH, Lin CW, Wen SL, Hsieh-Li HM, Li H: Stat5 constitutive activation rescues defects in spinal muscular atrophy. Hum Mol Genet. 2007, 16: 499-514. 10.1093\/hmg\/ddl482.","journal-title":"Hum Mol Genet"},{"key":"795_CR32","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1016\/S0021-9258(18)48292-0","volume":"262","author":"J Meyerovitch","year":"1987","unstructured":"Meyerovitch J, Farfel Z, Sack J, Shechter Y: Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. J Biol Chem. 1987, 262: 6658-6662.","journal-title":"J Biol Chem"},{"key":"795_CR33","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1172\/JCI117951","volume":"95","author":"N Cohen","year":"1995","unstructured":"Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1995, 95: 2501-2509. 10.1172\/JCI117951.","journal-title":"J Clin Invest"},{"key":"795_CR34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1385\/BTER:80:2:159","volume":"80","author":"W Ding","year":"2001","unstructured":"Ding W, Hasegawa T, Hosaka H, Peng D, Takahashi K, Seko Y: Effect of long-term treatment with vanadate in drinking water on KK mice with genetic non-insulin-dependent diabetes mellitus. Biol Trace Elem Res. 2001, 80: 159-174. 10.1385\/BTER:80:2:159.","journal-title":"Biol Trace Elem Res"},{"key":"795_CR35","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jinorgbio.2008.12.003","volume":"103","author":"KH Thompson","year":"2009","unstructured":"Thompson KH, Lichter J, LeBel C, Scaife MC, McNeill JH, Orvig C: Vanadium treatment of type 2 diabetes: a view to the future. J Inorg Biochem. 2009, 103: 554-558. 10.1016\/j.jinorgbio.2008.12.003.","journal-title":"J Inorg Biochem"},{"key":"795_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jat.2550100307","volume":"10","author":"JL Paternain","year":"1990","unstructured":"Paternain JL, Domingo JL, Gomez M, Ortega A, Corbella J: Developmental toxicity of vanadium in mice after oral administration. J Appl Toxicol. 1990, 10: 181-186. 10.1002\/jat.2550100307.","journal-title":"J Appl Toxicol"},{"key":"795_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.toxlet.2006.07.343","volume":"170","author":"P Villani","year":"2007","unstructured":"Villani P, Cordelli E, Leopardi P, Siniscalchi E, Veschetti E, Fresegna AM, Crebelli R: Evaluation of genotoxicity of oral exposure to tetravalent vanadium in vivo. Toxicol Lett. 2007, 170: 11-18. 10.1016\/j.toxlet.2006.07.343.","journal-title":"Toxicol Lett"},{"key":"795_CR38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF02991416","volume":"30","author":"D Sanchez","year":"1991","unstructured":"Sanchez D, Ortega A, Domingo JL, Corbella J: Developmental toxicity evaluation of orthovanadate in the mouse. Biol Trace Elem Res. 1991, 30: 219-226. 10.1007\/BF02991416.","journal-title":"Biol Trace Elem Res"},{"key":"795_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0378-4274(85)90151-1","volume":"26","author":"JL Domingo","year":"1985","unstructured":"Domingo JL, Llobet JM, Corbella J: Protection of mice against the lethal effects of sodium metavanadate: a quantitative comparison of a number of chelating agents. Toxicol Lett. 1985, 26: 95-99. 10.1016\/0378-4274(85)90151-1.","journal-title":"Toxicol Lett"},{"key":"795_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/jat.2550060507","volume":"6","author":"JL Domingo","year":"1986","unstructured":"Domingo JL, Llobet JM, Tomas JM, Corbella J: Influence of chelating agents on the toxicity, distribution and excretion of vanadium in mice. J Appl Toxicol. 1986, 6: 337-341. 10.1002\/jat.2550060507.","journal-title":"J Appl Toxicol"},{"key":"795_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/BF02783877","volume":"69","author":"DJ Sanchez","year":"1999","unstructured":"Sanchez DJ, Colomina MT, Domingo JL, Corbella J: Prevention by sodium 4,5-dihydroxybenzene-1,3-disulfonate (Tiron) of vanadium-induced behavioral toxicity in rats. Biol Trace Elem Res. 1999, 69: 249-259. 10.1007\/BF02783877.","journal-title":"Biol Trace Elem Res"},{"key":"795_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/BF01075942","volume":"153","author":"JL Domingo","year":"1995","unstructured":"Domingo JL, Gomez M, Sanchez DJ, Llobet JM, Keen CL: Toxicology of vanadium compounds in diabetic rats: the action of chelating agents on vanadium accumulation. Mol Cell Biochem. 1995, 153: 233-240. 10.1007\/BF01075942.","journal-title":"Mol Cell Biochem"},{"key":"795_CR43","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/cbdv.200890136","volume":"5","author":"EJ Baran","year":"2008","unstructured":"Baran EJ: Vanadium detoxification: chemical and biochemical aspects. Chem Biodivers. 2008, 5: 1475-1484. 10.1002\/cbdv.200890136.","journal-title":"Chem Biodivers"},{"key":"795_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0162-0134(00)00032-5","volume":"80","author":"EJ Baran","year":"2000","unstructured":"Baran EJ: Oxovanadium(IV) and oxovanadium(V) complexes relevant to biological systems. J Inorg Biochem. 2000, 80: 1-10. 10.1016\/S0162-0134(00)00032-5.","journal-title":"J Inorg Biochem"},{"key":"795_CR45","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1021\/ic050749g","volume":"45","author":"PC Wilkins","year":"2006","unstructured":"Wilkins PC, Johnson MD, Holder AA, Crans DC: Reduction of vanadium(V) by L-ascorbic acid at low and neutral pH: kinetic, mechanistic, and spectroscopic characterization. Inorg Chem. 2006, 45: 1471-1479. 10.1021\/ic050749g.","journal-title":"Inorg Chem"},{"key":"795_CR46","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.nbd.2006.07.004","volume":"24","author":"LK Tsai","year":"2006","unstructured":"Tsai LK, Tsai MS, Lin TB, Hwu WL, Li H: Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol Dis. 2006, 24: 286-295. 10.1016\/j.nbd.2006.07.004.","journal-title":"Neurobiol Dis"},{"key":"795_CR47","doi-asserted-by":"publisher","DOI":"10.1385\/0896034410","volume-title":"Basic Cell Culture Protocols","author":"JW Pollard","year":"1997","unstructured":"Pollard JW, Walker JM: Basic Cell Culture Protocols. 1997, Totowa, NJ: Humana Press Inc."},{"key":"795_CR48","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbrc.2009.11.090","volume":"391","author":"RG Gogliotti","year":"2010","unstructured":"Gogliotti RG, Hammond SM, Lutz C, Didonato CJ: Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy. Biochem Biophys Res Commun. 2010, 391: 517-522. 10.1016\/j.bbrc.2009.11.090.","journal-title":"Biochem Biophys Res Commun"},{"key":"795_CR49","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jneumeth.2006.11.002","volume":"161","author":"ME Butchbach","year":"2007","unstructured":"Butchbach ME, Edwards JD, Schussler KR, Burghes AH: A novel method for oral delivery of drug compounds to the neonatal SMNDelta7 mouse model of spinal muscular atrophy. J Neurosci Methods. 2007, 161: 285-290. 10.1016\/j.jneumeth.2006.11.002.","journal-title":"J Neurosci Methods"},{"key":"795_CR50","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.nbd.2007.04.009","volume":"27","author":"ME Butchbach","year":"2007","unstructured":"Butchbach ME, Edwards JD, Burghes AH: Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy. Neurobiol Dis. 2007, 27: 207-219. 10.1016\/j.nbd.2007.04.009.","journal-title":"Neurobiol Dis"},{"key":"795_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.expneurol.2008.02.025","volume":"212","author":"BF El-Khodor","year":"2008","unstructured":"El-Khodor BF, Edgar N, Chen A, Winberg ML, Joyce C, Brunner D, Suarez-Farinas M, Heyes MP: Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy. Exp Neurol. 2008, 212: 29-43. 10.1016\/j.expneurol.2008.02.025.","journal-title":"Exp Neurol"},{"key":"795_CR52","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/j.1460-9568.2010.07164.x","volume":"31","author":"T Furuse","year":"2010","unstructured":"Furuse T, Wada Y, Hattori K, Yamada I, Kushida T, Shibukawa Y, Masuya H, Kaneda H, Miura I, Seno N, Kanda T, Hirose R, Toki S, Nakanishi K, Kobayashi K, Sezutsu H, Gondo Y, Noda T, Yuasa S, Wakana S: Phenotypic characterization of a new Grin1 mutant mouse generated by ENU mutagenesis. Eur J Neurosci. 2010, 31: 1281-1291. 10.1111\/j.1460-9568.2010.07164.x.","journal-title":"Eur J Neurosci"},{"key":"795_CR53","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/cne.21483","volume":"504","author":"GI Keshet","year":"2007","unstructured":"Keshet GI, Tolwani RJ, Trejo A, Kraft P, Doyonnas R, Clayberger C, Weimann JM, Blau HM: Increased host neuronal survival and motor function in BMT Parkinsonian mice: involvement of immunosuppression. J Comp Neurol. 2007, 504: 690-701. 10.1002\/cne.21483.","journal-title":"J Comp Neurol"},{"key":"795_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ijc.22277","volume":"120","author":"RS Ray","year":"2007","unstructured":"Ray RS, Ghosh B, Rana A, Chatterjee M: Suppression of cell proliferation, induction of apoptosis and cell cycle arrest: chemopreventive activity of vanadium in vivo and in vitro. Int J Cancer. 2007, 120: 13-23. 10.1002\/ijc.22277.","journal-title":"Int J Cancer"},{"key":"795_CR55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12011-011-9215-6","volume":"146","author":"W Cui","year":"2012","unstructured":"Cui W, Cui H, Peng X, Fang J, Zuo Z, Liu X, Wu B: Dietary vanadium induces lymphocyte apoptosis in the bursa of Fabricius of broilers. Biol Trace Elem Res. 2012, 146: 59-67. 10.1007\/s12011-011-9215-6.","journal-title":"Biol Trace Elem Res"},{"key":"795_CR56","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S0092-8674(00)80367-0","volume":"90","author":"Q Liu","year":"1997","unstructured":"Liu Q, Fischer U, Wang F, Dreyfuss G: The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell. 1997, 90: 1013-1021. 10.1016\/S0092-8674(00)80367-0.","journal-title":"Cell"},{"key":"795_CR57","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/sj.ejhg.5200286","volume":"7","author":"AL Patrizi","year":"1999","unstructured":"Patrizi AL, Tiziano F, Zappata S, Donati MA, Neri G, Brahe C: SMN protein analysis in fibroblast, amniocyte and CVS cultures from spinal muscular atrophy patients and its relevance for diagnosis. Eur J Hum Genet. 1999, 7: 301-309. 10.1038\/sj.ejhg.5200286.","journal-title":"Eur J Hum Genet"},{"key":"795_CR58","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.nbd.2008.05.014","volume":"31","author":"LK Tsai","year":"2008","unstructured":"Tsai LK, Tsai MS, Ting CH, Wang SH, Li H: Restoring Bcl-x(L) levels benefits a mouse model of spinal muscular atrophy. Neurobiol Dis. 2008, 31: 361-367. 10.1016\/j.nbd.2008.05.014.","journal-title":"Neurobiol Dis"},{"key":"795_CR59","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1172\/JCI57291","volume":"121","author":"CM Lutz","year":"2011","unstructured":"Lutz CM, Kariya S, Patruni S, Osborne MA, Liu D, Henderson CE, Li DK, Pellizzoni L, Rojas J, Valenzuela DM, Murphy AJ, Winberg ML, Monani UR: Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest. 2011, 121: 3029-3041. 10.1172\/JCI57291.","journal-title":"J Clin Invest"},{"key":"795_CR60","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/hmg\/ddp510","volume":"19","author":"ME Butchbach","year":"2010","unstructured":"Butchbach ME, Singh J, Thorsteinsdottir M, Saieva L, Slominski E, Thurmond J, Andresson T, Zhang J, Edwards JD, Simard LR, Pellizzoni L, Jarecki J, Burghes AH, Gurney ME: Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet. 2010, 19: 454-467. 10.1093\/hmg\/ddp510.","journal-title":"Hum Mol Genet"},{"key":"795_CR61","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","volume":"28","author":"KD Foust","year":"2010","unstructured":"Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, Le TT, Morales PR, Rich MM, Burghes AH, Kaspar BK: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010, 28: 271-274. 10.1038\/nbt.1610.","journal-title":"Nat Biotechnol"},{"key":"795_CR62","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1093\/hmg\/ddr275","volume":"20","author":"TT Le","year":"2011","unstructured":"Le TT, McGovern VL, Alwine IE, Wang X, Massoni-Laporte A, Rich MM, Burghes AH: Temporal requirement for high SMN expression in SMA mice. Hum Mol Genet. 2011, 20: 3578-3591. 10.1093\/hmg\/ddr275.","journal-title":"Hum Mol Genet"},{"key":"795_CR63","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/mus.21654","volume":"42","author":"S Rudnik-Schoneborn","year":"2010","unstructured":"Rudnik-Schoneborn S, Vogelgesang S, Armbrust S, Graul-Neumann L, Fusch C, Zerres K: Digital necroses and vascular thrombosis in severe spinal muscular atrophy. Muscle Nerve. 2010, 42: 144-147. 10.1002\/mus.21654.","journal-title":"Muscle Nerve"},{"key":"795_CR64","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jpeds.2009.01.071","volume":"155","author":"Q Araujo Ade","year":"2009","unstructured":"Araujo Ade Q, Araujo M, Swoboda KJ: Vascular perfusion abnormalities in infants with spinal muscular atrophy. J Pediatr. 2009, 155: 292-294. 10.1016\/j.jpeds.2009.01.071.","journal-title":"J Pediatr"},{"key":"795_CR65","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.ymthe.2006.02.008","volume":"13","author":"MS Tsai","year":"2006","unstructured":"Tsai MS, Chiu YT, Wang SH, Hsieh-Li HM, Lian WC, Li H: Abolishing Bax-dependent apoptosis shows beneficial effects on spinal muscular atrophy model mice. Mol Ther. 2006, 13: 1149-1155. 10.1016\/j.ymthe.2006.02.008.","journal-title":"Mol Ther"},{"key":"795_CR66","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1172\/JCI41615","volume":"120","author":"MA Passini","year":"2010","unstructured":"Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, O'Riordan CR, Klinger KW, Shihabuddin LS, Cheng SH: CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest. 2010, 120: 1253-1264. 10.1172\/JCI41615.","journal-title":"J Clin Invest"},{"key":"795_CR67","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1212\/01.wnl.0000231139.26253.d0","volume":"67","author":"CC Weihl","year":"2006","unstructured":"Weihl CC, Connolly AM, Pestronk A: Valproate may improve strength and function in patients with type III\/IV spinal muscle atrophy. Neurology. 2006, 67: 500-501. 10.1212\/01.wnl.0000231139.26253.d0.","journal-title":"Neurology"},{"key":"795_CR68","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1111\/j.1468-1331.2007.01992.x","volume":"14","author":"LK Tsai","year":"2007","unstructured":"Tsai LK, Yang CC, Hwu WL, Li H: Valproic acid treatment in six patients with spinal muscular atrophy. Eur J Neurol. 2007, 14: e8-9.","journal-title":"Eur J Neurol"},{"key":"795_CR69","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1212\/WNL.59.4.609","volume":"59","author":"M Kinali","year":"2002","unstructured":"Kinali M, Mercuri E, Main M, De Biasia F, Karatza A, Higgins R, Banks LM, Manzur AY, Muntoni F: Pilot trial of albuterol in spinal muscular atrophy. Neurology. 2002, 59: 609-610. 10.1212\/WNL.59.4.609.","journal-title":"Neurology"},{"key":"795_CR70","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1081\/CLT-100102425","volume":"37","author":"DG Barceloux","year":"1999","unstructured":"Barceloux DG: Vanadium. J Toxicol Clin Toxicol. 1999, 37: 265-278. 10.1081\/CLT-100102425.","journal-title":"J Toxicol Clin Toxicol"},{"key":"795_CR71","volume-title":"Trace Elements in Human Nutrition and Health","author":"International Atomic Energy Agency WHO, Food and Agriculture Organization of the United Nations","year":"1996","unstructured":"International Atomic Energy Agency WHO, Food and Agriculture Organization of the United Nations: Trace Elements in Human Nutrition and Health. 1996, Geneva, Switzerland: World Health Organization"},{"key":"795_CR72","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1089\/acm.2008.0165","volume":"14","author":"F Deruelle","year":"2008","unstructured":"Deruelle F, Baron B: Vitamin C: is supplementation necessary for optimal health?. J Altern Complement Med. 2008, 14: 1291-1298. 10.1089\/acm.2008.0165.","journal-title":"J Altern Complement Med"},{"key":"795_CR73","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1093\/hmg\/9.16.2451","volume":"9","author":"UR Monani","year":"2000","unstructured":"Monani UR, Coovert DD, Burghes AH: Animal models of spinal muscular atrophy. Hum Mol Genet. 2000, 9: 2451-2457. 10.1093\/hmg\/9.16.2451.","journal-title":"Hum Mol Genet"},{"key":"795_CR74","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0896-6273(00)80173-7","volume":"17","author":"TL Deckwerth","year":"1996","unstructured":"Deckwerth TL, Elliott JL, Knudson CM, Johnson EM, Snider WD, Korsmeyer SJ: BAX is required for neuronal death after trophic factor deprivation and during development. Neuron. 1996, 17: 401-411. 10.1016\/S0896-6273(00)80173-7.","journal-title":"Neuron"},{"key":"795_CR75","first-page":"196","volume":"22","author":"S Li","year":"1991","unstructured":"Li S, Zhang T, Yang Z, Gou X: Distribution of vanadium in tissues of nonpregnant and pregnant Wistar rats [in Chinese]. Hua Xi Yi Ke Da Xue Xue Bao. 1991, 22: 196-200.","journal-title":"Hua Xi Yi Ke Da Xue Xue Bao"},{"key":"795_CR76","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.metabol.2005.08.021","volume":"55","author":"AL Edel","year":"2006","unstructured":"Edel AL, Kopilas M, Clark TA, Aguilar F, Ganguly PK, Heyliger CE, Pierce GN: Short-term bioaccumulation of vanadium when ingested with a tea decoction in streptozotocin-induced diabetic rats. Metabolism. 2006, 55: 263-270. 10.1016\/j.metabol.2005.08.021.","journal-title":"Metabolism"},{"key":"795_CR77","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.metabol.2011.10.007","volume":"61","author":"TA Clark","year":"2012","unstructured":"Clark TA, Heyliger CE, Kopilas M, Edel AL, Junaid A, Aguilar F, Smyth DD, Thliveris JA, Merchant M, Kim HK, Pierce GN: A tea\/vanadate decoction delivered orally over 14 months to diabetic rats induces long-term glycemic stability without organ toxicity. Metabolism. 2012, 61: 742-753. 10.1016\/j.metabol.2011.10.007.","journal-title":"Metabolism"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-11-38.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1741-7015-11-38\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-11-38","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-11-38.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:26:38Z","timestamp":1630542398000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-11-38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,14]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["795"],"URL":"https:\/\/doi.org\/10.1186\/1741-7015-11-38","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,14]]},"assertion":[{"value":"24 September 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"38"}}